Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

4YCU

Crystal structure of cladosporin in complex with human lysyl-tRNA synthetase

Summary for 4YCU
Entry DOI10.2210/pdb4ycu/pdb
Related4YCV 4YCW
DescriptorLysine--tRNA ligase, Aminoacyl tRNA synthase complex-interacting multifunctional protein 2, cladosporin, ... (6 entities in total)
Functional Keywordsinhibitor, complex, lysrs, cladosporin, ligase- ligase inhibitor complex, ligase/ ligase inhibitor
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains3
Total formula weight124639.37
Authors
Fang, P.,Wang, J.,Guo, M. (deposition date: 2015-02-20, release date: 2015-06-10, Last modification date: 2024-11-20)
Primary citationFang, P.,Han, H.,Wang, J.,Chen, K.,Chen, X.,Guo, M.
Structural Basis for Specific Inhibition of tRNA Synthetase by an ATP Competitive Inhibitor.
Chem. Biol., 22:734-744, 2015
Cited by
PubMed Abstract: Pharmaceutical inhibitors of aminoacyl-tRNA synthetases demand high species and family specificity. The antimalarial ATP-mimetic cladosporin selectively inhibits Plasmodium falciparum LysRS (PfLysRS). How the binding to a universal ATP site achieves the specificity is unknown. Here we report three crystal structures of cladosporin with human LysRS, PfLysRS, and a Pf-like human LysRS mutant. In all three structures, cladosporin occupies the class defining ATP-binding pocket, replacing the adenosine portion of ATP. Three residues holding the methyltetrahydropyran moiety of cladosporin are critical for the specificity of cladosporin against LysRS over other class II tRNA synthetase families. The species-exclusive inhibition of PfLysRS is linked to a structural divergence beyond the active site that mounts a lysine-specific stabilizing response to binding cladosporin. These analyses reveal that inherent divergence of tRNA synthetase structural assembly may allow for highly specific inhibition even through the otherwise universal substrate binding pocket and highlight the potential for structure-driven drug development.
PubMed: 26074468
DOI: 10.1016/j.chembiol.2015.05.007
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.1 Å)
Structure validation

229183

PDB entries from 2024-12-18

PDB statisticsPDBj update infoContact PDBjnumon